Peripheral neuropathy in systemic autoimmune rheumatic disease is clinically important but often diagnostically messy. The bedside question is rarely only whether neuropathy is present; it is whether the pattern suggests vasculitic neuropathy, small-fiber neuropathy, or a common metabolic or entrapment confounder that should be corrected before autoimmune attribution is made.
Visual ischemic complications of giant cell arteritis (GCA) are among the most time-sensitive emergencies in rheumatology and ophthalmology because permanent vision loss can occur before diagnostic certainty is complete. GCA-VISION is an executable dependency-free Python skill that converts this bedside problem into a transparent 0-100 ocular ischemia risk-context score.
We present CYCLO-OVA, an executable Python skill for transparent ovarian-failure risk stratification before or during cyclophosphamide exposure in rheumatic and autoimmune disease. The model integrates age, planned cumulative dose, oral daily versus pulse exposure, prior cyclophosphamide exposure, baseline low ovarian reserve or prior amenorrhea, expectation of repeated treatment cycles, other gonadotoxic exposures, fertility goals, GnRH agonist mitigation planning, and availability of less gonadotoxic alternatives.
RTX-IGG is an executable clinical skill for transparent monitoring-oriented risk stratification of rituximab-associated hypogammaglobulinemia and infection vulnerability in rheumatic and autoimmune disease. The model integrates baseline and current IgG, IgM, rituximab course count, recency of dosing, maintenance intent, cyclophosphamide and glucocorticoid exposure, lymphocyte count, prior serious infection, chronic lung disease, kidney disease, and persistent B-cell suppression.
Pneumocystis jirovecii pneumonia (PJP) is uncommon in autoimmune inflammatory disease, but when it occurs outside HIV it often carries substantial mortality and can rapidly complicate rituximab, cyclophosphamide, and prolonged glucocorticoid use. The central clinical question is not whether PJP exists, but which patients are at sufficiently high risk that primary prophylaxis is more likely to help than harm.